Micro Labs Limited — Clindamycin Exporter Profile
Indian Pharmaceutical Exporter · #3 for Clindamycin · $4.7M export value · DGFT Verified
Micro Labs Limited is the #3 Indian exporter of Clindamycin with $4.7M in export value and 93 verified shipments. Micro Labs Limited holds a 5.2% market share in Clindamycin exports across 4 countries. The company exports 76 pharmaceutical products worth $463.6M across 21 therapeutic categories.
Micro Labs Limited — Clindamycin Export Profile: Buyers & Destinations
Where Does Micro Labs Limited Export Clindamycin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $3.5M | 86 | 92.8% |
| UNITED KINGDOM | $214.0K | 5 | 5.7% |
| SRI LANKA | $55.7K | 4 | 1.5% |
| OMAN | $0 | 1 | 0.0% |
Micro Labs Limited exports Clindamycin to 4 countries. The largest destination is UNITED STATES accounting for 92.8% of Micro Labs Limited's Clindamycin shipments, followed by UNITED KINGDOM (5.7%) and SRI LANKA (1.5%). These destinations reflect Micro Labs Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Clindamycin from Micro Labs Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCE SERVICES, LLC | UNITED STATES | $2.3M | 58 |
| EVERSANA LIFE SCIENCE SERVICES LLC | UNITED STATES | $1.1M | 26 |
| BROWN AND BURK UK LIMITED | UNITED KINGDOM | $193.9K | 4 |
| EVERSANA LIFE SCIENCE SERVICES | UNITED STATES | $88.5K | 2 |
| MICRO HEALTHCARE (PRIVATE) LIMITED | SRI LANKA | $55.7K | 4 |
| BROWN & BURK UK LTD | UNITED KINGDOM | $20.1K | 1 |
| MR.SHANKAR G./MR.SUDHAKARAN PULLATI | OMAN | $0 | 1 |
Micro Labs Limited supplies Clindamycin to 7 buyers globally. The largest buyer is EVERSANA LIFE SCIENCE SERVICES, LLC (UNITED STATES), followed by EVERSANA LIFE SCIENCE SERVICES LLC (UNITED STATES) and BROWN AND BURK UK LIMITED (UNITED KINGDOM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Clindamycin Export Value and How Much Does Micro Labs Limited Contribute?
India exported $47.6M worth of Clindamycin through 7,242 shipments from 527 suppliers to 144 countries, serving 1,029 buyers globally. Micro Labs Limited contributes $4.7M to this total, accounting for 5.2% of India's Clindamycin exports. Micro Labs Limited ships Clindamycin to 4 countries through 7 buyers.
What Is the Average Shipment Value for Micro Labs Limited's Clindamycin Exports?
Micro Labs Limited's average Clindamycin shipment value is $50.0K per consignment, based on 93 shipments totaling $4.7M. The largest destination is UNITED STATES (92.8% of Micro Labs Limited's Clindamycin exports).
How Does Micro Labs Limited Compare to Other Indian Clindamycin Exporters?
Micro Labs Limited ranks #3 among 527 Indian Clindamycin exporters with a 5.2% market share. The top 3 exporters are ENCUBE ETHICALS PRIVATE LIMITED ($14.6M), AUROBINDO PHARMA LTD ($9.4M), GLENMARK PHARMACEUTICALS LIMITED ($4.7M). Micro Labs Limited processed 93 shipments to 4 destination countries.
What Clindamycin Formulations Does Micro Labs Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CLINDAMYCIN HYDROCHLORIDE CAPSULES, USP | $500.0K | 10 |
| CLINDAMYCIN HYDROCHLORIDE CAPSULES, USP300MG ANDA NO 207402, NDC NO 42571-252-01. (INV,QTY.48216 ) (PACK 100S)NOS | $150.0K | 3 |
| CLINDAMYCIN HYDROCHLORIDE CAPSULES USP150MG ANDA NO 207402 NDC NO 42571-251-01 (PACK 100S) ( INV. QTY67500 )NOS | $150.0K | 3 |
| CLINDAMYCIN HYDROCHLORIDE CAPSULES, USP 300MG ANDA NO: 207402, NDC NO: 42571-252-01. INV.QTY 29184) (PACK 100 | $150.0K | 3 |
| CLINDAMYCIN HYDROCHLORIDE CAPSULES, USP 300MG ANDA NO: 207402, NDC NO: 42571-252-01. INV.QTY 38976) (PACK 100 | $150.0K | 3 |
| CLINDAMYCIN HYDROCHLORIDE CAPSULES USP300MG ANDA NO 207402 NDC NO 42571-252-01 (PACK 100S) ( INV. QTY19440 )NOS | $134.0K | 3 |
| CLINDAMYCIN HYDROCHLORIDE CAPSULES USP300MG ANDA NO 207402 NDC NO 42571-252-01 (PACK 100S) ( INV. QTY 19176 ) TNOS | $132.9K | 3 |
| CLINDAMYCIN HYDROCHLORIDE CAPSULES, USP 300MG ANDA NO: 207402, NDC NO: 42571-252-01. INV.QTY 19128) (PACK 100 | $132.9K | 3 |
| CLINDAMYCIN HYDROCHLORIDE CAPSULES, USP 300MG ANDA NO: 207402, NDC NO: 42571-252-01,(INV.QTY.19200) PACK 100 | $132.8K | 3 |
| CLINDAMYCIN HYDROCHLORIDE CAPSULES USP 300MG ANDA NO 207402 NDC NO 42571-251-01 (PACK 100S) ( INV. QTY19152 )NOS | $132.8K | 3 |
Micro Labs Limited exports 49 distinct Clindamycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CLINDAMYCIN HYDROCHLORIDE CAPSULES, USP with 10 shipments worth $500.0K.
Regulatory Requirements: Exporting Clindamycin to Key Markets
What Micro Labs Limited must comply with to export Clindamycin to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Micro Labs Limited Compare to Nearest Clindamycin Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | AUROBINDO PHARMA LTD | $9.4M | 188 | 2 | $50.0K |
| 5 | GLENMARK PHARMACEUTICALS LIMITED | $4.7M | 199 | 6 | $23.6K |
| 3 | MICRO LABS LIMITED ★ | $4.7M | 93 | 4 | $50.0K |
| 4 | AUROBINDO PHARMA LIMITED | $3.1M | 63 | 2 | $50.0K |
| 6 | BIOMATRIX HEALTHCARE PRIVATE LIMITED | $3.1M | 62 | 6 | $50.0K |
Micro Labs Limited ranks #3 among 527 Indian Clindamycin exporters. Average shipment value of $50.0K compared to the market average of $90.3K. The closest competitors by value are AUROBINDO PHARMA LTD and GLENMARK PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Clindamycin Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 1,184 | 16.3% |
| SAHAR AIR | 1,119 | 15.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 966 | 13.3% |
| DELHI AIR | 674 | 9.3% |
| NHAVA SHEVA SEA (INNSA1) | 437 | 6.0% |
| JNPT/ NHAVA SHEVA SEA | 328 | 4.5% |
| Bombay Air | 309 | 4.3% |
| Delhi Air | 201 | 2.8% |
Geopolitical & Trade Policy Impact on Micro Labs Limited's Clindamycin Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Micro Labs Limited. The Israel-Iran conflict has intensified tensions in the Red Sea, leading to increased shipping costs and potential delays. These disruptions can affect supply chain efficiency and profitability, necessitating strategic adjustments in logistics and distribution channels.
Conversely, the U.S.-China trade tensions have prompted the United States to diversify its pharmaceutical supply sources, creating an opportunity for Indian exporters to capture a larger market share. Micro Labs can leverage this shift by emphasizing its compliance with U.S. regulatory standards and ensuring a reliable supply chain.
The recent India-European Union Free Trade Agreement, signed in January 2026, is poised to eliminate tariffs on most European pharmaceutical exports to India. While this enhances market access for European manufacturers, it also intensifies competition for Indian exporters. Micro Labs must enhance its value proposition through innovation, cost efficiency, and adherence to EU regulatory standards to maintain its competitive edge. (en.wikipedia.org)
Micro Labs Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for pharmaceutical exporters. Micro Labs Limited has demonstrated a commitment to quality, as evidenced by its recognition as India’s Most Technically and Scientifically Advanced Pharmaceutical Manufacturing Company in 2024. This accolade reflects the company's adherence to stringent manufacturing practices and international guidelines. (einnews.com)
However, the evolving regulatory landscape, including the EU's Falsified Medicines Directive and the U.S. FDA's stringent quality requirements, necessitates continuous investment in compliance infrastructure. Micro Labs must proactively adapt to these changes to ensure uninterrupted market access and maintain its reputation for quality.
About Micro Labs Limited
Micro Labs Limited exports 76 products worth $463.6M. Beyond Clindamycin, top products include Amoxicillin, Potassium, Gabapentin, Losartan, Esomeprazole. View the complete Micro Labs Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Clindamycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Clindamycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Micro Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 96 individual customs records matching Micro Labs Limited exporting Clindamycin, covering 49 formulations to 4 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 144+ countries, 1,029+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Clindamycin Export Data from Micro Labs Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Micro Labs Limited's Clindamycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Micro Labs Limited
Full Company Profile →
76 products · $463.6M total trade · 21 categories
Clindamycin Stats
Company Overview
Top Products by Micro Labs Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Micro Labs Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Clindamycin. For current shipment-level data, contact TransData Nexus.